Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

Jiangxi Jemincare Group Receives Clinical Trial Approvals for Two Innovative Biologics in the US and China

Fineline Cube Jan 9, 2024

Jiangxi Jemincare Group, a biopharmaceutical company based in China, has announced that it has received...

Company Medical Device

ShuWen Biotech’s MammaTyper Diagnostic Kit Receives NMPA Approval for Breast Cancer Molecular Classification

Fineline Cube Jan 9, 2024

ShuWen Biotech Co., Ltd, a biopharmaceutical company based in Zhejiang, has announced that its MammaTyper...

Company Drug

Allist Pharmaceuticals’ Furmonertinib and AstraZeneca’s Enhertu Earn Breakthrough Designations in China for NSCLC Treatments

Fineline Cube Jan 9, 2024

The Center for Drug Evaluation (CDE) in China has indicated on its website that Allist...

Company Drug

Thederma’s TAP-1503 Cream Receives Priority Review Status for Pediatric Atopic Dermatitis Treatment in China

Fineline Cube Jan 9, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Thederma’s TAP-1503 cream is...

Company Drug

Innovent Biologics’ Mazdutide Achieves Positive Results in Phase III Clinical Trial for Overweight or Obesity

Fineline Cube Jan 9, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Deals

Bain Capital-Backed Tenacia Strikes Deal with Praxis Precision Medicines for Essential Tremor Treatment

Fineline Cube Jan 9, 2024

Tenacia, a central nervous system (CNS) specialist incubated by Bain Capital, has entered into an...

Company Drug

Abbisko Therapeutics’ Pimicotinib Earns Orphan Drug Designation from EMA for TGCT Treatment

Fineline Cube Jan 9, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...

Company Drug

Gilead’s Descovy Receives Additional Indication Approval from China’s NMPA for HIV-1 PrEP

Fineline Cube Jan 9, 2024

Gilead Sciences, Inc. (NASDAQ: GILD), a major player in the pharmaceutical industry in the U.S.,...

Company Deals

Bebig Medical Group Secures Over USD 14 Million in Series B Financing to Boost Radiotherapy Technology

Fineline Cube Jan 9, 2024

Bebig Medical Group, a Germany-based provider of high-quality radiation therapy products with a presence in...

Company Deals

Chengdu Kanghua Strikes Licensing Deal with HilleVax for Recombinant Norovirus Vaccine

Fineline Cube Jan 9, 2024

Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...

Company Drug

CSBIO’s Multi-Kinase Inhibitor CSCJC3456 Gets Green Light for Clinical Trials in Advanced Solid Tumors

Fineline Cube Jan 9, 2024

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced...

Company Deals

Triastek Partners with Kangerjia to Develop 3D-Printed Modified Drugs for Sleep Disorders

Fineline Cube Jan 9, 2024

Triastek Inc., a China-based pharmaceutical-focused 3D printing company, has entered into a partnership with fellow...

Company Drug

Aidea Pharmaceutical Receives NMPA Approval to Clinically Test HIV-1 Treatment ACC017

Fineline Cube Jan 9, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, has announced...

Company

WuXi Biologics Expands Manufacturing Capacity to 36,000 Liters at Worcester Facility

Fineline Cube Jan 9, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Green Light for Phase Ib/II Study of SHR-A1921 Combo in Advanced Solid Tumors

Fineline Cube Jan 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Deals

Biocytogen Strikes Exclusive Licensing Deal with US-Based Radiance Biopharma for Innovative BsADC

Fineline Cube Jan 9, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a leading biopharmaceutical company based in China ,...

Company Drug

MSD Advances Four Oncology Candidates to Late-Stage Trials, Including Partnerships with Kelun-Biotech and Orion

Fineline Cube Jan 8, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced significant progress in its oncology pipeline...

Company Deals

AstraZeneca Secures Exclusive Rights to Omniose’s Enzyme Platform for Bacterial Vaccine Development

Fineline Cube Jan 8, 2024

AstraZeneca (AZ; NASDAQ: AZN) has secured an exclusive licensing agreement with biotechnology firm Omniose for...

Company Policy / Regulatory

China’s NHSA Aims to Balance Drug Prices with New Monitoring System by March 2024

Fineline Cube Jan 8, 2024

The National Healthcare Security Administration (NHSA) has issued a notification aimed at fostering inter-provincial price...

Company Deals

AbbVie Partners with Umoja Biopharma to Develop Next-Generation CAR-T Therapies

Fineline Cube Jan 8, 2024

AbbVie (NYSE: ABBV) has entered into a collaboration agreement with Umoja Biopharma, a US-based company...

Posts pagination

1 … 445 446 447 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.